I am a
Home I AM A Search Login

Papers of the Week

Papers: 29 Aug 2020 - 4 Sep 2020

Pharmacology/Drug Development


2020 Aug 28

CNS Drugs

Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.


The US Food and Drug Administration has approved orally administered 100-mg and 200-mg doses of lasmiditan for the acute treatment of migraine, with or without aura. Having a unique mechanism of action, lasmiditan is the first and only Food and Drug Administration-approved serotonin 5-HT receptor agonist.